Bi-specific antibodies targeting both EpCAM and CD73 can selectively target EpCAM+ carcinoma-derived EVs secreted from various cancer cells and inhibit CD73 EV-mediated immune suppression compared to CD73-targeting alone [106]. This evidence concerns the gene NT5E and cancer.